Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Europe Acts On Counterfeit Drugs

by Rick Mullin
February 21, 2011 | A version of this story appeared in Volume 89, Issue 8

The European Parliament has approved a directive guarding against the shipment of counterfeit active pharmaceutical ingredients (APIs) into the European Union. Under the Directive on Falsified Medicines, shipments of APIs must include a statement from health authorities in the country of origin that the product was manufactured according to current Good Manufacturing Practice (cGMP) standards or the equivalent. The directive requires that API manufacturers in the EU register with national health authorities and outlines an auditing regimen for suppliers outside the EU. It also establishes a public database on cGMP certification. “We have much to celebrate,” says Guy Villax, CEO of Lisbon-based Hovione and an advocate for international monitoring of API shipments on behalf of the European Fine Chemicals Group.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.